1-20 of 439
btk inhibitors
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Introduction to a review series on small-molecule targeted therapies for lymphoid malignancies

Free
Andrew W. Roberts, Freda K. Stevenson
Journal: Blood
Blood (2021) 138 (13): 1089.
https://doi.org/10.1182/blood.2021012674
Published: 2021
Journal Articles

Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies

Free
Clinical Trials & Observations
Deborah M. Stephens, John C. Byrd
Journal: Blood
Blood (2021) 138 (13): 1099–1109.
https://doi.org/10.1182/blood.2020006783
Published: 2021
Journal Articles

CLL cells are moved by the MARCKS brothers

Free
Jan A. Burger
Journal: Blood
Blood (2021) 138 (7): 503–504.
https://doi.org/10.1182/blood.2021011650
Published: 2021
Journal Articles

MARCKS affects cell motility and response to BTK inhibitors in CLL

Free
Laura Beckmann, Valeska Berg, Clarissa Dickhut, Clare Sun, Olaf Merkel, Johannes Bloehdorn, Sandra Robrecht, Marc Seifert, Alexandra da Palma Guerreiro, Julia Claasen, Stefan Loroch, Matteo Oliverio, Chingiz Underbayev, Lauren Vaughn, Daniel Thomalla, Malte F. Hülsemann, Eugen Tausch, Kirsten Fischer, Anna Maria Fink, Barbara Eichhorst, Albert Sickmann, Clemens M. Wendtner, Stephan Stilgenbauer, Michael Hallek, Adrian Wiestner, René P. Zahedi, Lukas P. Frenzel
Journal: Blood
Blood (2021) 138 (7): 544–556.
https://doi.org/10.1182/blood.2020009165
Published: 2021
Includes: Supplemental data
Journal Articles

Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia

Free
Ishwarya Murali, Siddha Kasar, Aishath Naeem, Svitlana Tyekucheva, Jasneet K. Khalsa, Emily M. Thrash, Gilad Itchaki, Dimitri Livitz, Ignaty Leshchiner, Shuai Dong, Stacey M. Fernandes, Gad Getz, Amy Johnson, Jennifer R. Brown
Journal: Blood
Blood (2021) 138 (1): 44–56.
https://doi.org/10.1182/blood.2020006765
Published: 2021
Includes: Supplemental data
Journal Articles

Treon SP, Castillo JJ, Skarbnik AP, et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients. Blood. 2020;135(21):1912-1915.

Free
Journal: Blood
Blood (2021) 137 (11): 1561.
https://doi.org/10.1182/blood.2021010938
Published: 2021
Journal Articles

Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib

Free
Clinical Trials & Observations
Clare Sun, Pia Nierman, Ellen K. Kendall, Jean Cheung, Michael Gulrajani, Sarah E. M. Herman, Christopher Pleyer, Inhye E. Ahn, Maryalice Stetler-Stevenson, Constance M. Yuan, Irina Maric, Erika M. Gaglione, Hailey M. Harris, Stefania Pittaluga, Min Hui Wang, Priti Patel, Mohammed Z. H. Farooqui, Raquel Izumi, Ahmed Hamdy, Todd Covey, Adrian Wiestner
Journal: Blood
Blood (2020) 136 (1): 93–105.
https://doi.org/10.1182/blood.2019003715
Published: 2020
Includes: Supplemental data
Journal Articles

Occupy BTK: the key to controlling CLL

Free
Philip A. Thompson
Journal: Blood
Blood (2020) 136 (1): 4–6.
https://doi.org/10.1182/blood.2020005877
Published: 2020
Journal Articles

BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax

Free
Clinical Trials & Observations Brief Report
Victor S. Lin, Thomas E. Lew, Sasanka M. Handunnetti, Piers Blombery, Tamia Nguyen, David A. Westerman, Bryone J. Kuss, Constantine S. Tam, Andrew W. Roberts, John F. Seymour, Mary Ann Anderson
Journal: Blood
Blood (2020) 135 (25): 2266–2270.
https://doi.org/10.1182/blood.2020004782
Published: 2020
Includes: Supplemental data
Journal Articles

Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BT K/PLCG2 mutations

Free
Fabienne Lucas, Karylin Larkin, C. Thomas Gregory, Shelley Orwick, Tzyy-Jye Doong, Arletta Lozanski, Gerard Lozanski, Shrilekha Misra, Apollinaire Ngankeu, Hatice Gulcin Ozer, Deepa Sampath, Shanmugapriya Thangavadivel, Selen A. Yilmaz, Kerry A. Rogers, John C. Byrd, Jennifer A. Woyach, James S. Blachly
Journal: Blood
Blood (2020) 135 (24): 2192–2195.
https://doi.org/10.1182/blood.2019003722
Published: 2020
Includes: Supplemental data
Journal Articles

The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients

Free
Clinical Trials & Observations
Steven P. Treon, Jorge J. Castillo, Alan P. Skarbnik, Jacob D. Soumerai, Irene M. Ghobrial, Maria Luisa Guerrera, Kirsten Meid, Guang Yang
Journal: Blood
Blood (2020) 135 (21): 1912–1915.
https://doi.org/10.1182/blood.2020006288
Published: 2020
Journal Articles

How I treat Waldenström macroglobulinemia

Free
Clinical Trials & Observations
Meletios A. Dimopoulos, Efstathios Kastritis
Journal: Blood
Blood (2019) 134 (23): 2022–2035.
https://doi.org/10.1182/blood.2019000725
Published: 2019
Journal Articles

Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials

Free
Clinical Trials & Observations
Jennifer A. Woyach
Journal: Blood
Blood (2019) 134 (21): 1796–1801.
https://doi.org/10.1182/blood.2019001321
Published: 2019
Journal Articles

Diverging Clonal Evolution during Sequential Therapy with Chemoimmunotherapy Followed By BTK Inhibitors

Free
Inhye E Ahn, MD, Yun-Ching Chen, PhD, Chingiz Underbayev, MD PhD, Erika M Gaglione, Clare Sun, MD, Susan Soto, Pia Nierman, Mehdi Pirooznia, MD PhD, Adrian Wiestner, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 850.
https://doi.org/10.1182/blood-2019-122142
Published: 2019
Journal Articles

Utilization and Early Discontinuation of First-Line Ibrutinib for Patients with Chronic Lymphocytic Leukemia Treated in the Community Oncology Setting in the United States

Free
Scott F. Huntington, MD MPH, Pamela R. Soulos, Paul M. Barr, MD, Ryan Jacobs, MD, Frederick Lansigan, MD, Oreofe O. Odejide, MD MPH, Lee S. Schwartzberg, MD, Amy J. Davidoff, PhD MS, Cary P Gross, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 797.
https://doi.org/10.1182/blood-2019-122054
Published: 2019
Journal Articles

Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II Study

Free
Yuqin Song, MD PhD, Yongping Song, MD, Lihong Liu, Mingzhi Zhang, Zhiming Li, Chunyan Ji, Wei Xu, MD PhD, Ting Liu, MD, Bing Xu, Xin Wang, MD PhD, Sujun Gao, Huilai Zhang, MD, Yu Hu, Yan Li, Ying Cheng, Haiyan Yang, Junning Cao, MD, Zunmin Zhu, Jianda Hu, PhD, Wei Zhang, Hongmei Jing, Kaiyang Ding, Zhengguang Lu, Bin Zhang, PhD, Renbin Zhao, Zhixin Xu, Jun Zhu, BS
Journal: Blood
Blood (2019) 134 (Supplement_1): 755.
https://doi.org/10.1182/blood-2019-126305
Published: 2019
Journal Articles

Outcomes Following Early Relapse in Patients with Mantle Cell Lymphoma

Free
David A. Bond, MD, Jeffrey M. Switchenko, PhD MS, Kami J. Maddocks, MD, Michael C. Churnetski, Subir Goyal, Krithika Shanmugasundaram, MD, Oscar Calzada, BS, Bhaskar Kolla, MBBS, Veronika Bachanova, MD PhD, James N. Gerson, MD, Stefan K. Barta, MD MRCP, MS, Yazeed Sawalha, MD, Brian T. Hill, MD, Peter Martin, FRCPC, MD MS, Max J. Gordon, MD, Alexey Danilov, MD PhD, Natalie S Grover, MD, Stephanie Mathews, MD, Madelyn Burkart, MD, Reem Karmali, MD, Nilanjan Ghosh, MD PhD, Steven I Park, MD, Narendranath Epperla, MDMS, Talha Badar, MD, Jin Guo, MD, Mehdi Hamadani, MD, Timothy S. Fenske, MD, Mary-Kate Malecek, MD, Brad S. Kahl, MD, Christopher R. Flowers, MD MS, Kristie A. Blum, MD, Jonathon B. Cohen, MDMS
Journal: Blood
Blood (2019) 134 (Supplement_1): 753.
https://doi.org/10.1182/blood-2019-128415
Published: 2019
Journal Articles

KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase 2 ZUMA-2 Study

Free
Michael L. Wang, MD, Javier Munoz, MD, Andre Goy, MD, Frederick L. Locke, MD, Caron A. Jacobson, MD MMSc, Brian T. Hill, MD, John M. Timmerman, MD, Houston Holmes, MD, Samantha Jaglowski, MDMPH, Ian W. Flinn, MD PhD, Peter A. McSweeney, MD, David B. Miklos, MD PhD, John M. Pagel, MD PhD DSc, Marie Jose Kersten, MD PhD, Weimin Peng, MS, Lianqing Zheng, PhD, John M. Rossi, MS, Rajul K. Jain, MD, Arati V. Rao, MD, Patrick M Reagan, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 754.
https://doi.org/10.1182/blood-2019-126064
Published: 2019
Journal Articles

Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study

Free
Sasanka M. Handunnetti, MBBS, FRACP, FRCPA, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Rodney J. Hicks, MB BS (Hons), MD FRACP, FAHMS, Besiat Birbirsa, B.N., Mathias Bressel, M.Sc, Juliana Di Iulio, PhD, David Alan Westerman, MBBS, FRCPA, FRACP, Stephen Lade, MBBS, FRCPA, Rishu Agarwal, Mark A. Dawson, PhD MBBS, Sarah-Jane Dawson, MD PhD, Rachel Koldej, David Ritchie, MD PhD, John F. Seymour, MBBS, PhD FRACP, Andrew W. Roberts, MBBS, PhD, Constantine S. Tam, MBBS, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 756.
https://doi.org/10.1182/blood-2019-126619
Published: 2019
Journal Articles

A Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel BTK Inhibitor, Dtrmwxhs-12 (DTRM-12), in Combination with Everolimus and Pomalidomide in Patients with Relapsed/Refractory CLL, DLBCL or Other B-Cell Lymphomas

Free
Anthony R. Mato, MDMSCE, Stephen J Schuster, MD, Francine M. Foss, MD, Iris Isufi, MD, Wei Ding, MD PhD, Danielle M. Brander, MD, Andrea Sitlinger, MD, Han W. Tun, MD, Muhamad Alhaj Moustafa, MD, Kaitlin Kennard, RN, BSN, Cara M King, MPH, Amber Koehler, PA-C, MS, Casey Aitken, Wei He, PhD, Albert Kearney, PhD, Min Gui, PhD, Barry Douglas Anderson, MD PhD, Allison C. Rosenthal, DO, Lindsey E. Roeker, MD, Scott F. Huntington, MD MPH
Journal: Blood
Blood (2019) 134 (Supplement_1): 810.
https://doi.org/10.1182/blood-2019-126192
Published: 2019